Australia’s Therapeutic Goods Administration increased first-time inspections of drug manufacturing facilities by 16 percent in the second half of 2016, compared to the same period a year earlier, according to the agency’s latest performance report.

Initial inspections have jumped significantly since the TGA implemented a risk-based strategy prioritizing initial inspections over re-inspections.

Reviews of complementary drugs increased by 164 percent to 235. The increased scrutiny accounts for an 8 percent year-on-year increase in the proportion of drugs with compliance breaches.